Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bromocriptine mesylate
Drug ID BADD_D00305
Description Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Indications and Usage For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
Marketing Status approved; investigational
ATC Code G02CB01; N04BC01
DrugBank ID DB01200
KEGG ID D00780
MeSH ID D001971
PubChem ID 31100
TTD Drug ID D06YFA
NDC Product Code 0574-0106; 55486-1561; 30698-201; 0781-5325; 0378-7096; 68012-258; 60687-286; 65841-654; 73212-035; 51927-2274; 30698-202; 68382-110
UNII FFP983J3OD
Synonyms Bromocriptine | 2-Bromo-alpha-ergokryptine | 2 Bromo alpha ergokryptine | Bromocryptin | 2-Bromoergokryptine | 2 Bromoergokryptine | Bromocriptin | 2-Bromoergocryptine | 2 Bromoergocryptine | 2-Bromo-alpha-ergocryptine | 2 Bromo alpha ergocryptine | CB-154 | CB 154 | CB154 | Parlodel | 2-Bromoergocryptine Mesylate | 2 Bromoergocryptine Mesylate | Mesylate, 2-Bromoergocryptine | Bromocriptine Mesylate | Mesylate, Bromocriptine | 2-Bromoergocryptine Methanesulfonate | 2 Bromoergocryptine Methanesulfonate | Methanesulfonate, 2-Bromoergocryptine
Chemical Information
Molecular Formula C33H44BrN5O8S
CAS Registry Number 22260-51-1
SMILES CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C 4)Br)C)O.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis10.02.02.006; 24.12.04.027--
Vasospasm24.04.02.002--Not Available
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Sudden onset of sleep17.15.04.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Ocular discomfort06.08.03.008--Not Available
Temperature intolerance08.01.09.022--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Neurological symptom17.02.05.010--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Impulse-control disorder19.18.01.002--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Cardiac valve disease02.07.02.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Gastrointestinal ulcer07.04.04.002--Not Available
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.010--Not Available
Neoplasm recurrence16.16.02.004--Not Available
Psychotic disorder19.03.01.002--
Hypersexuality19.08.03.005--Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages